- $82.41m
- $59.05m
- $28.70m
- 38
- 42
- 35
- 30
Annual balance sheet for Vaxart, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 127 | 166 | 95.7 | 39.7 | 51.7 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.334 | 0.071 | 0.02 | 3.01 | 12 |
| Prepaid Expenses | |||||
| Total Current Assets | 129 | 169 | 99.5 | 45.5 | 68.3 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 8.32 | 19.8 | 41.3 | 36.6 | 29.1 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 153 | 221 | 154 | 91.8 | 166 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 11.8 | 10.8 | 17.9 | 13.7 | 90.9 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 29.2 | 33.6 | 43.3 | 34 | 107 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 123 | 188 | 111 | 57.8 | 58.9 |
| Total Liabilities & Shareholders' Equity | 153 | 221 | 154 | 91.8 | 166 |
| Total Common Shares Outstanding |